¼¼°èÀÇ Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)
Vascular Endothelial Growth Factor Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀåÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú ´Ù¾çÇÑ Ç÷°ü °ü·Ã Áúȯ ¹× »óŸ¦ Ä¡·áÇϱâ À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ±Ù ¸î ³âµ¿¾È Å« °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇп¡ ´ëÇØ ÀÚ¼¼È÷ Á¶»çÇÏ°í ½ÃÀå ±Ô¸ð, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, °æÀï ȯ°æ¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» ´ã°í ÀÖ½À´Ï´Ù. ºÐ¼® ±â°£Àº 2024³âºÎÅÍ 2031³â±îÁöÀ̸ç, ÀÌÇØ°ü°èÀڵ鿡°Ô Àü·«Àû ÀÇ»ç°áÁ¤°ú »ç¾÷ ¼ºÀå¿¡ µµ¿òÀÌ µÇ´Â ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è VEGF ½ÃÀåÀº 2024-2031³â CAGR 10.7%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³â ½ÃÀå ±Ô¸ð´Â 2¾ï 6,170¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2031³â¿¡´Â 5¾ï 3,311¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
½ÃÀå °¡Ä¡ ÃßÁ¤Ä¡(2024³â) : 2¾ï 6,170¸¸ ´Þ·¯
¿¹»ó ½ÃÀå °¡Ä¡(2031³â) : 5¾ï 3,311¸¸ ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 10.7%.
VEGF ½ÃÀå - º¸°í¼ ¹üÀ§ :
ÀÌ Á¶»ç º¸°í¼´Â VEGF ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÏ°í ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ» °Á¶Çϸç, VEGF´Â »õ·Î¿î Ç÷°üÀ» Çü¼ºÇÏ´Â °úÁ¤ÀÎ Ç÷°ü½Å»ý¿¡¼ ±× ¿ªÇÒ·Î ÀÎÇØ Ç×¾Ï Ä¡·áÀÇ Áß¿äÇÑ Ç¥ÀûÀÔ´Ï´Ù. Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï°ú ³ëÈ °ü·Ã Ȳ¹Ýº¯¼º(AMD), ´ç´¢¸Á¸·º´Áõ ¹× ±âŸ ¸Á¸· ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ï°ú ³ëÈ °ü·Ã ÁúȯÀÇ ¹ß»ý·ü Áõ°¡¿Í ÀÇÇÐ ¿¬±¸ ¹× Ä¡·á¹ýÀÇ ¹ßÀüÀº VEGF Ç¥Àû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·ü Áõ°¡´Â VEGF ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¾Ï¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀÌ¿¡ »õ·Î¿î Ç÷°üÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ ¾Ï Ä¡·áÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AMD¿Í °°Àº ³ëÈ °ü·Ã ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾à¹° Àü´Þ ½Ã½ºÅÛ ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ ±â¼ú ¹ßÀüÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈµÈ Ä¡·á¹ýÀ¸·Î À̾îÁ® ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ä¡·á¹ý °³¼±°ú VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí VEGF ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·á´Â °í°¡À̱⠶§¹®¿¡ ƯÈ÷ ÀÇ·á ½Ã½ºÅÛÀÌ ¹ß´ÞÇÏÁö ¾ÊÀº Áö¿ª¿¡¼´Â ÀϺΠȯÀÚÀÇ Á¢±Ù¼ºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, VEGF ¾ïÁ¦Á¦ÀÇ ºÎÀÛ¿ëÀº °íÇ÷¾Ð, »óó Ä¡À¯ Àå¾Ö¿Í °°Àº ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ ȯÀÚ¿¡°Ô À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú ±ä ½ÂÀÎ ÀýÂ÷µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ´ëü ¿ä¹ý°úÀÇ °æÀï°ú °áÇÕÇÏ¿© ½ÃÀå È®´ë¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
VEGF ½ÃÀå¿¡´Â ¼ºÀå°ú Çõ½ÅÀÇ Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·áÁ¦ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× Á¦³×¸¯ ÀǾàǰÀÇ °³¹ßÀº ´õ Àú·ÅÇÑ Ä¡·á¹ýÀÇ ±æÀ» ¿¾î ´õ ¸¹Àº ȯÀÚ±º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϰí, VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î Ä¡·á ¿ëµµ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ½ÃÀå ´Ù°¢È °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ °øµ¿¿¬±¸´Â ȹ±âÀûÀÎ Ä¡·á¹ýÀ» âÃâÇϰí VEGF ½ÃÀåÀÇ Àúº¯À» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå È®´ëÀÇ ¶Ç ´Ù¸¥ ±âȸÀÔ´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®µé
2024-2031³â VEGF ½ÃÀåÀÇ ¿¹»ó CAGRÀº?
VEGF ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
VEGF ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ªÀº?
¼¼°è VEGF ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
VEGF ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ±âȸ´Â?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§/ ºÐ·ù
½ÃÀåÀÇ Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
Æ÷ÇÔ°ú Á¦¿Ü
Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
Á¦Ç° Çõ½Å/°³¹ß µ¿Çâ
Á¦4Àå ÁÖ¿ä ³»¿ë
ÃÑÀÌÀÍ ºÐ¼®
±ÔÁ¦ ½Ã³ª¸®¿À
¹ë·ùüÀÎ ºÐ¼®
VEGF ½ÃÀå ¸ÅÃâ ºñ±³(2019³â°ú 2023³â)
Á¦5Àå ½ÃÀå ¹è°æ
°Å½Ã°æÁ¦ ¿äÀÎ
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
½ÃÀå ¿ªÇÐ
Á¦6Àå COVID-19 À§±â ºÐ¼®
COVID-19ÇöÀç Åë°è¿Í ÇâÈÄ ¿µÇâ °¡´É¼º
ÇöÀç GDP ¿¹ÃøÀ̶ó°í ¿¹»óµÇ´Â ¿µÇâ
2008³â°ú ºñ±³ÇÑ ÇöÀç °æÁ¦ ¿¹Ãø °æÁ¦ ºÐ¼®
COVID-19·Î ¿µÇ⠺м®
VEGF À¯Çüº°
VGEF ¿ëµµº°
VEGF ¹ßÇö ¼÷ÁÖº°
ÃÖÁ¾»ç¿ëÀÚº°
Áö¿ªº°
2023³â ½ÃÀå ½Ã³ª¸®¿À
Á¦7Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ¼ö¿ä(±Ý¾× ¶Ç´Â ±Ô¸ð) ºÐ¼®
°ú°Å ½ÃÀå ¸ÅÃ⠺м®(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ¸ÅÃâ ¿¹Ãø(2024³â-2031³â)
Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
Àý´ëÀû ÀÌÀÍ ±âȸ ºÐ¼®
Á¦8Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VEGF À¯Çüº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : VEGF À¯Çüº°(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : VEGF À¯Çüº°(2024³â-2032³â)
Àΰ£ VEGF
Áã VEGF
Åä³¢ VEGF
·¡Æ® VEGF
±âŸ
VEGF À¯Çüº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦9Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VGEF ¿ëµµº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : VGEF ¿ëµµº°(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : VGEF ¿ëµµº°(2024³â-2032³â)
¼¼Æ÷¹è¾ç
¼¼Æ÷ ±â¹Ý Ä¡·á
ÀǾàǰ °³¹ß
À¯ÀüÀÚ Ä¡·á
Èñ±ÍÁúȯ Ä¡·á
º´¿ë¿ä¹ý
â»ó Ä¡À¯ ¿¬±¸
Ç÷¾×ÇÐ ¿¬±¸
»À Çü¼º
Ç×Ç÷°ü ½Å»ý ¿ä¹ý
VGEF ¿ëµµº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦10Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ¹ßÇö ¼÷ÁÖº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ¹ßÇö ¼÷ÁÖº°(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : ¹ßÇö ¼÷ÁÖº°(2024³â-2032³â)
HEK293 ¼¼Æ÷
´ëÀå±Õ
°ïÃæ ¼¼Æ÷
CHO
NS0
±âŸ
¹ßÇö ¼÷ÁÖº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦11Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024³â-2032³â)
Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
¿¬±¸¼¾ÅÍ ¹× Çмú±â°ü
CMO/CDMO
±âŸ ÃÖÁ¾»ç¿ëÀÚ
ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦12Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : Áö¿ªº°
¼·Ð
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(2019³â-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : Áö¿ªº°(2024³â-2032³â)
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
³²¾Æ½Ã¾Æ
µ¿¾Æ½Ã¾Æ
¿À¼¼¾Æ´Ï¾Æ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áö¿ªº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦13Àå ºÏ¹ÌÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦15Àå À¯·´ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦16Àå ³²¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦17Àå µ¿¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦18Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦19Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦20Àå ½ÃÀå ±¸Á¶ ºÐ¼®
±â¾÷ °èÃþº° ½ÃÀå ºÐ¼®
ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
½ÃÀå ÀÔÁö ºÐ¼®
Á¦21Àå °æÀï ºÐ¼®
°æÀï ´ë½Ãº¸µå
°æÀï º¥Ä¡¸¶Å·
°æÀï ±¸µµ
Thermo Fisher Scientific
Merck KGaA
Bio-Rad Laboratories, Inc.
Bio-Techne(R&D Systems, Inc.)
GenScript
Miltenyi Biotec.
Abcam PLC.
Sino Biological Inc.
Cell Signaling Technology, Inc.
ACROBiosystems
STEMCELL Technologies
Creative Bioarray
PeproTech
Applied Biological Materials(abm) Inc.
GenWay Biotech
Leadgene Biomedical, Inc.
Boster Bio
Prospec-Tany Technogene Ltd.
Proteintech Group, Inc
Á¦22Àå »ç¿ëµÈ ÀüÁ¦Á¶°Ç°ú µÎÀÚ¾î
Á¦23Àå Á¶»ç ¹æ¹ý
LSH
The Vascular Endothelial Growth Factor (VEGF) market has gained significant traction in recent years, driven by advances in medical research and the growing need for effective therapies to treat a range of vascular-related diseases and conditions. This comprehensive report from Persistence Market Research delves into the dynamics of the VEGF market, providing key insights into market size, growth drivers, challenges, opportunities, and competitive landscape. The analysis covers the period from 2024 to 2031, offering stakeholders valuable information to guide their strategic decisions and business growth.
The global VEGF market is projected to expand at a CAGR of 10.7% from 2024 to 2031, with a market value estimated at USD 261.7 million in 2024 and expected to reach USD 533.1 million by 2031.
Key Insights:
Market Value Estimate (2024): USD 261.7 Million
Projected Market Value (2031): USD 533.1 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 10.7%
VEGF Market - Report Scope:
The report provides a comprehensive analysis of the VEGF market, highlighting key factors driving growth. VEGF is a significant target for anti-cancer therapies due to its role in angiogenesis, the process of forming new blood vessels. Anti-VEGF therapies are used to treat various types of cancers, as well as other conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. The growing incidence of cancer and age-related diseases, coupled with advancements in medical research and treatment methods, has fueled demand for VEGF-targeting therapies.
Market Growth Drivers:
The increasing prevalence of cancer worldwide is a major driver for the VEGF market. As cancer cells require new blood vessels to grow and spread, anti-VEGF therapies have become a cornerstone in the treatment of various cancers. Additionally, the rising incidence of age-related diseases, such as AMD, has further contributed to market growth. Technological advancements in drug delivery systems and personalized medicine approaches have led to more effective and targeted therapies, fostering market expansion. The demand for improved treatments and the development of new applications for VEGF inhibitors are key factors driving the market's growth.
Market Restraints:
Despite its potential, the VEGF market faces certain challenges. The high cost of anti-VEGF therapies can limit access for some patients, especially in regions with less developed healthcare systems. Additionally, side effects associated with VEGF inhibitors, such as hypertension and impaired wound healing, can pose risks to patients. Regulatory hurdles and the lengthy process of drug approval also impact market growth. These factors, combined with competition from alternative therapies, can restrain the market's expansion.
Market Opportunities:
The VEGF market presents significant opportunities for growth and innovation. The development of biosimilars and generic versions of anti-VEGF therapies offers a pathway to more affordable treatments, expanding access to a broader patient base. Ongoing research into new therapeutic applications for VEGF inhibitors provides potential for market diversification. Furthermore, collaborations between pharmaceutical companies and research institutions can lead to groundbreaking treatments and expand the VEGF market's reach. Investment in emerging markets, where demand for advanced therapies is growing, represents another opportunity for market expansion.
Key Questions Addressed in the Report:
What is the expected CAGR for the VEGF market between 2024 and 2031?
What are the major factors driving growth in the VEGF market?
Which regions hold the largest share of the VEGF market?
Who are the key players in the global VEGF market?
What are the main opportunities for growth in the VEGF market?
Competitive Landscape and Business Strategies:
The VEGF market features a competitive landscape with leading players like Genentech, Regeneron Pharmaceuticals, and Amgen. These companies focus on innovation, research and development, and strategic collaborations to maintain their market position. Genentech's Avastin, a widely used anti-VEGF drug, is a prominent example of a successful product in this sector. Regeneron Pharmaceuticals has also gained a significant market share with its product Eylea, used in the treatment of AMD and other retinal diseases.
Key business strategies include the development of new drug formulations, expansion into new therapeutic areas, and partnerships with other pharmaceutical companies. Companies are also focusing on expanding their presence in emerging markets and exploring biosimilar opportunities to increase their market reach.
Key Companies Profiled:
Thermo Fisher Scientific Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
Bio-Techne [R&D Systems, Inc.]
GenScript
Miltenyi Biotec.
Abcam PLC.
Sino Biological Inc.
Cell Signaling Technology, Inc.
ACROBiosystems
STEMCELL Technologies
VEGF Market Segmentation:
VEGF Market by VEGF Type:
Human VEGF
Mouse VEGF
Rat VEGF
Rabbit VEGF
Others VEGF
VEGF Market by Expression Host:
CHO
E. Coli
HEK
NSO
Insect Cells
Others
VEGF Market by Application:
Cell Culture
Cell-based Therapy
Drug Development
Gene Therapy
Rare Disease treatment
Wound Healing Research
Combination Therapies
Hematology Research
Osteogenesis
Anti-Angiogenic Therapy
VEGF Market by End User:
Pharmaceutical & Biotechnology Companies
Academic Institutes
CMOs & CDMOs
Other End Users
Research Centers & Laboratories
Hospital-attached Laboratories (HALs)
VEGF Market by Region:
North America VEGF Market
Latin America VEGF Market
Europe VEGF Market
South Asia VEGF Market
East Asia VEGF Market
Oceania VEGF Market
Middle East & Africa VEGF Market
Table of Contents
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion And Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Inclusions
4.1. Gross Margin Analysis
4.2. Regulatory Scenario
4.3. Value Chain Analysis
4.4. VEGF Market Value Comparison 2019 and 2023
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Growth Factor Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Advancements in Protein Characterization Techniques
5.2.2. Increase in R&D Funding and Grants
5.2.3. High Prevalence of Chronic Diseases
5.2.4. New Product Launch
5.2.5. Rising Research Activities for Rare Disease Indications
5.2.6. Emergence of Novel Patented Technologies
5.2.7. Collaborations and Agreements between Manufacturers
5.2.8. Regulatory Approvals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. Current COVID-19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID-19 and Impact Analysis
6.4.1. By VEGF Types
6.4.2. By VGEF Application
6.4.3. By VEGF Expression Hosts
6.4.4. By End User
6.4.5. By Region
6.5. 2023 Market Scenario
7. Global Vascular Endothelial Growth Factor (VEGF) Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Types
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By VEGF Types, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VEGF Types, 2024-2031
8.3.1. Human VEGF
8.3.2. Mouse VEGF
8.3.3. Rabbit VEGF
8.3.4. RAT VEGF
8.3.5. Others
8.4. Market Attractiveness Analysis By VEGF Types
9. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VGEF Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By VGEF Application, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Application, 2024-2031
9.3.1. Cell Culture
9.3.2. Cell-Based Therapy
9.3.3. Drug Development
9.3.4. Gene Therapy
9.3.5. Rare Disease Treatment
9.3.6. Combination Therapies
9.3.7. Wound Healing Research
9.3.8. Hematology Research
9.3.9. Osteogenesis
9.3.10. Anti-Angiogenic Therapy
9.4. Market Attractiveness Analysis By VGEF Application
10. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Expression Hosts
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By VGEF Expression Hosts, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Expression Hosts, 2024-2031
10.3.1. HEK293 cells
10.3.2. E. coli
10.3.3. Insect Cells
10.3.4. CHO
10.3.5. NS0
10.3.6. Others
10.4. Market Attractiveness Analysis By VGEF Expression Hosts
11. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
11.3.1. Pharmaceutical and Biotechnology Companies
11.3.2. Research Centers & Academic Institutes
11.3.3. CMO and CDMO
11.3.4. Other End Users
11.3.4.1. Research laboratories
11.3.4.2. Hospital-Attached laboratories (HALs)
11.4. Market Attractiveness Analysis By End User
12. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region
13. North America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By VEGF Types
13.3.3. By VGEF Application
13.3.4. By VGEF Expression Hosts
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By VEGF Types
13.4.3. By VGEF Application
13.4.4. By VGEF Expression Hosts
13.4.5. By End User
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. U.S. Vascular Endothelial Growth Factor (VEGF) Market
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By VEGF Types
13.7.1.2.2. By VGEF Application
13.7.1.2.3. By VGEF Expression Hosts
13.7.1.2.4. By End User
13.7.2. Canada Vascular Endothelial Growth Factor (VEGF) Market
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By VEGF Types
13.7.2.2.2. By VGEF Application
13.7.2.2.3. By VGEF Expression Hosts
13.7.2.2.4. By End User
14. Latin America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By VEGF Types
14.3.3. By VGEF Application
14.3.4. By VGEF Expression Hosts
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By VEGF Types
14.4.3. By VGEF Application
14.4.4. By VGEF Expression Hosts
14.4.5. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. Brazil Vascular Endothelial Growth Factor (VEGF) Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By VEGF Types
14.7.1.2.2. By VGEF Application
14.7.1.2.3. By VGEF Expression Hosts
14.7.1.2.4. By End User
14.7.2. Argentina Vascular Endothelial Growth Factor (VEGF) Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By VEGF Types
14.7.2.2.2. By VGEF Application
14.7.2.2.3. By VGEF Expression Hosts
14.7.2.2.4. By End User
14.7.3. Mexico Vascular Endothelial Growth Factor (VEGF) Market
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By VEGF Types
14.7.3.2.2. By VGEF Application
14.7.3.2.3. By VGEF Expression Hosts
14.7.3.2.4. By End User
15. Europe Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Nordic Countries
15.3.1.9. Rest of Europe
15.3.2. By VEGF Types
15.3.3. By VGEF Application
15.3.4. By VGEF Expression Hosts
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By VEGF Types
15.4.3. By VGEF Application
15.4.4. By VGEF Expression Hosts
15.4.5. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Germany Vascular Endothelial Growth Factor (VEGF) Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By VEGF Types
15.7.1.2.2. By VGEF Application
15.7.1.2.3. By VGEF Expression Hosts
15.7.1.2.4. By End User
15.7.2. France Vascular Endothelial Growth Factor (VEGF) Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By VEGF Types
15.7.2.2.2. By VGEF Application
15.7.2.2.3. By VGEF Expression Hosts
15.7.2.2.4. By End User
15.7.3. Italy Vascular Endothelial Growth Factor (VEGF) Market
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By VEGF Types
15.7.3.2.2. By VGEF Application
15.7.3.2.3. By VGEF Expression Hosts
15.7.3.2.4. By End User
15.7.4. Spain Vascular Endothelial Growth Factor (VEGF) Market
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By VEGF Types
15.7.4.2.2. By VGEF Application
15.7.4.2.3. By VGEF Expression Hosts
15.7.4.2.4. By End User
15.7.5. U.K. Vascular Endothelial Growth Factor (VEGF) Market
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By VEGF Types
15.7.5.2.2. By VGEF Application
15.7.5.2.3. By VGEF Expression Hosts
15.7.5.2.4. By End User
15.7.6. Benelux Vascular Endothelial Growth Factor (VEGF) Market
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By VEGF Types
15.7.6.2.2. By VGEF Application
15.7.6.2.3. By VGEF Expression Hosts
15.7.6.2.4. By End User
15.7.7. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Market
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By VEGF Types
15.7.7.2.2. By VGEF Application
15.7.7.2.3. By VGEF Expression Hosts
15.7.7.2.4. By End User
15.7.8. Russia Vascular Endothelial Growth Factor (VEGF) Market
15.7.8.1. Introduction
15.7.8.2. Market Analysis and Forecast by Market Taxonomy
15.7.8.2.1. By VEGF Types
15.7.8.2.2. By VGEF Application
15.7.8.2.3. By VGEF Expression Hosts
15.7.8.2.4. By End User
16. South Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By VEGF Types
16.3.3. By VGEF Application
16.3.4. By VGEF Expression Hosts
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By VEGF Types
16.4.3. By VGEF Application
16.4.4. By VGEF Expression Hosts
16.4.5. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. India Vascular Endothelial Growth Factor (VEGF) Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By VEGF Types
16.7.1.2.2. By VGEF Application
16.7.1.2.3. By VGEF Expression Hosts
16.7.1.2.4. By End User
16.7.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By VEGF Types
16.7.2.2.2. By VGEF Application
16.7.2.2.3. By VGEF Expression Hosts
16.7.2.2.4. By End User
16.7.3. Malaysia Vascular Endothelial Growth Factor (VEGF) Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By VEGF Types
16.7.3.2.2. By VGEF Application
16.7.3.2.3. By VGEF Expression Hosts
16.7.3.2.4. By End User
16.7.4. Thailand Vascular Endothelial Growth Factor (VEGF) Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By VEGF Types
16.7.4.2.2. By VGEF Application
16.7.4.2.3. By VGEF Expression Hosts
16.7.4.2.4. By End User
17. East Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By VEGF Types
17.3.3. By VGEF Application
17.3.4. By VGEF Expression Hosts
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By VEGF Types
17.4.3. By VGEF Application
17.4.4. By VGEF Expression Hosts
17.4.5. By End User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. China Vascular Endothelial Growth Factor (VEGF) Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By VEGF Types
17.7.1.2.2. By VGEF Application
17.7.1.2.3. By VGEF Expression Hosts
17.7.1.2.4. By End User
17.7.2. Japan Vascular Endothelial Growth Factor (VEGF) Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By VEGF Types
17.7.2.2.2. By VGEF Application
17.7.2.2.3. By VGEF Expression Hosts
17.7.2.2.4. By End User
17.7.3. South Korea Vascular Endothelial Growth Factor (VEGF) Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By VEGF Types
17.7.3.2.2. By VGEF Application
17.7.3.2.3. By VGEF Expression Hosts
17.7.3.2.4. By End User
18. Oceania Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By VEGF Types
18.3.3. By VGEF Application
18.3.4. By VGEF Expression Hosts
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By VEGF Types
18.4.3. By VGEF Application
18.4.4. By VGEF Expression Hosts
18.4.5. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Australia Vascular Endothelial Growth Factor (VEGF) Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By VEGF Types
18.7.1.2.2. By VGEF Application
18.7.1.2.3. By VGEF Expression Hosts
18.7.1.2.4. By End User
18.7.2. New Zealand Vascular Endothelial Growth Factor (VEGF) Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By VEGF Types
18.7.2.2.2. By VGEF Application
18.7.2.2.3. By VGEF Expression Hosts
18.7.2.2.4. By End User
19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By VEGF Types
19.3.3. By VGEF Application
19.3.4. By VGEF Expression Hosts
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By VEGF Types
19.4.3. By VGEF Application
19.4.4. By VGEF Expression Hosts
19.4.5. By End User
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. GCC Countries Vascular Endothelial Growth Factor (VEGF) Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By VEGF Types
19.7.1.2.2. By VGEF Application
19.7.1.2.3. By VGEF Expression Hosts
19.7.1.2.4. By End User
19.7.2. Turkey Vascular Endothelial Growth Factor (VEGF) Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By VEGF Types
19.7.2.2.2. By VGEF Application
19.7.2.2.3. By VGEF Expression Hosts
19.7.2.2.4. By End User
19.7.3. South Africa Vascular Endothelial Growth Factor (VEGF) Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By VEGF Types
19.7.3.2.2. By VGEF Application
19.7.3.2.3. By VGEF Expression Hosts
19.7.3.2.4. By End User
19.7.4. North Africa Vascular Endothelial Growth Factor (VEGF) Market
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By VEGF Types
19.7.4.2.2. By VGEF Application
19.7.4.2.3. By VGEF Expression Hosts
19.7.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Device foot print by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Thermo Fisher Scientific
21.3.1.1. Overview & Key financials
21.3.1.2. Product Portfolio
21.3.1.3. Key Financials
21.3.1.4. Sales Footprint
21.3.1.5. SWOT Analysis
21.3.1.6. Analysis Commentary
21.3.1.7. Strategy Overview
21.3.2. Merck KGaA
21.3.2.1. Overview & Key financials
21.3.2.2. Product Portfolio
21.3.2.3. Key Financials
21.3.2.4. Sales Footprint
21.3.2.5. SWOT Analysis
21.3.2.6. Analysis Commentary
21.3.2.7. Strategy Overview
21.3.3. Bio-Rad Laboratories, Inc.
21.3.3.1. Overview & Key financials
21.3.3.2. Product Portfolio
21.3.3.3. Key Financials
21.3.3.4. Sales Footprint
21.3.3.5. SWOT Analysis
21.3.3.6. Analysis Commentary
21.3.3.7. Strategy Overview
21.3.4. Bio-Techne [R&D Systems, Inc.]
21.3.4.1. Overview & Key financials
21.3.4.2. Product Portfolio
21.3.4.3. Key Financials
21.3.4.4. Sales Footprint
21.3.4.5. SWOT Analysis
21.3.4.6. Analysis Commentary
21.3.4.7. Strategy Overview
21.3.5. GenScript
21.3.5.1. Overview & Key financials
21.3.5.2. Product Portfolio
21.3.5.3. Key Financials
21.3.5.4. Sales Footprint
21.3.5.5. SWOT Analysis
21.3.5.6. Analysis Commentary
21.3.5.7. Strategy Overview
21.3.6. Miltenyi Biotec.
21.3.6.1. Overview & Key financials
21.3.6.2. Product Portfolio
21.3.6.3. Key Financials
21.3.6.4. Sales Footprint
21.3.6.5. SWOT Analysis
21.3.6.6. Analysis Commentary
21.3.6.7. Strategy Overview
21.3.7. Abcam PLC.
21.3.7.1. Overview & Key financials
21.3.7.2. Product Portfolio
21.3.7.3. Key Financials
21.3.7.4. Sales Footprint
21.3.7.5. SWOT Analysis
21.3.7.6. Analysis Commentary
21.3.7.7. Strategy Overview
21.3.8. Sino Biological Inc.
21.3.8.1. Overview & Key financials
21.3.8.2. Product Portfolio
21.3.8.3. Key Financials
21.3.8.4. Sales Footprint
21.3.8.5. SWOT Analysis
21.3.8.6. Analysis Commentary
21.3.8.7. Strategy Overview
21.3.9. Cell Signaling Technology, Inc.
21.3.9.1. Overview & Key financials
21.3.9.2. Product Portfolio
21.3.9.3. Key Financials
21.3.9.4. Sales Footprint
21.3.9.5. SWOT Analysis
21.3.9.6. Analysis Commentary
21.3.9.7. Strategy Overview
21.3.10. ACROBiosystems
21.3.10.1. Overview & Key financials
21.3.10.2. Product Portfolio
21.3.10.3. Key Financials
21.3.10.4. Sales Footprint
21.3.10.5. SWOT Analysis
21.3.10.6. Analysis Commentary
21.3.10.7. Strategy Overview
21.3.11. STEMCELL Technologies
21.3.11.1. Overview & Key financials
21.3.11.2. Product Portfolio
21.3.11.3. Key Financials
21.3.11.4. Sales Footprint
21.3.11.5. SWOT Analysis
21.3.11.6. Analysis Commentary
21.3.11.7. Strategy Overview
21.3.12. Creative Bioarray
21.3.12.1. Overview & Key financials
21.3.12.2. Product Portfolio
21.3.12.3. Key Financials
21.3.12.4. Sales Footprint
21.3.12.5. SWOT Analysis
21.3.12.6. Analysis Commentary
21.3.12.7. Strategy Overview
21.3.13. PeproTech
21.3.13.1. Overview & Key financials
21.3.13.2. Product Portfolio
21.3.13.3. Key Financials
21.3.13.4. Sales Footprint
21.3.13.5. SWOT Analysis
21.3.13.6. Analysis Commentary
21.3.13.7. Strategy Overview
21.3.14. Applied Biological Materials (abm) Inc.
21.3.14.1. Overview & Key financials
21.3.14.2. Product Portfolio
21.3.14.3. Key Financials
21.3.14.4. Sales Footprint
21.3.14.5. SWOT Analysis
21.3.14.6. Analysis Commentary
21.3.14.7. Strategy Overview
21.3.15. GenWay Biotech
21.3.15.1. Overview & Key financials
21.3.15.2. Product Portfolio
21.3.15.3. Key Financials
21.3.15.4. Sales Footprint
21.3.15.5. SWOT Analysis
21.3.15.6. Analysis Commentary
21.3.15.7. Strategy Overview
21.3.16. Leadgene Biomedical, Inc.
21.3.16.1. Overview & Key financials
21.3.16.2. Product Portfolio
21.3.16.3. Key Financials
21.3.16.4. Sales Footprint
21.3.16.5. SWOT Analysis
21.3.16.6. Analysis Commentary
21.3.16.7. Strategy Overview
21.3.17. Boster Bio
21.3.17.1. Overview & Key financials
21.3.17.2. Product Portfolio
21.3.17.3. Key Financials
21.3.17.4. Sales Footprint
21.3.17.5. SWOT Analysis
21.3.17.6. Analysis Commentary
21.3.17.7. Strategy Overview
21.3.18. Prospec-Tany Technogene Ltd.
21.3.18.1. Overview & Key financials
21.3.18.2. Product Portfolio
21.3.18.3. Key Financials
21.3.18.4. Sales Footprint
21.3.18.5. SWOT Analysis
21.3.18.6. Analysis Commentary
21.3.18.7. Strategy Overview
21.3.19. Proteintech Group, Inc
21.3.19.1. Overview & Key financials
21.3.19.2. Product Portfolio
21.3.19.3. Key Financials
21.3.19.4. Sales Footprint
21.3.19.5. SWOT Analysis
21.3.19.6. Analysis Commentary
21.3.19.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology